Rare disease specialist firm Alexion is splashing out $8.4 billion to buy fellow US orphan drug developer Synageva biopharmaceuticals. The …
US biopharma firm Synageva has appointed Robert Bazemore as its chief operating officer. Reporting directly to the president and chief …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

